Published
Papers.

KPC-34

Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer

Kucera & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation

Short Summary of KPC34

The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia

Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer

DHA-dFdC

Short-term Toxicity Study of DHA-dFdC

Study of DHA-dFdC

Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside